Phase I and Clinical Pharmacology Citations 1-25 of 165 total displayed. Histone Deacetylase Inhibitors in Cancer Therapy Andrew A. Lane, Bruce A. Chabner JCO Nov 2009: 5459-5468. Abstract Full Text PDF CiteTrack Phase I Study of the Safety, Tolerability, and Pharmacokinetics of Oral CP-868,596, a Highly Specific Platelet-Derived Growth Factor Receptor Tyrosine Kinase Inhibitor in Patients With Advanced Cancers Nancy L. Lewis, Lionel D. Lewis, Joseph P. Eder, Nandi J. Reddy, Feng Guo, Kristen J. Pierce, Anthony J. Olszanski, Roger B. Cohen JCO Nov 2009: 5262-5269. Abstract Full Text PDF Data Supplement CiteTrack Phase I Active Immunotherapy With Combination of Two Chimeric, Human Epidermal Growth Factor Receptor 2, B-Cell Epitopes Fused to a Promiscuous T-Cell Epitope in Patients With Metastatic and/or Recurrent Solid Tumors Pravin T.P. Kaumaya, Kevin Chu Foy, Joan Garrett, Sharad V. Rawale, Daniele Vicari, Jennifer M. Thurmond, Tammy Lamb, Aruna Mani, Yahaira Kane, Catherine R. Balint, Donald Chalupa, Gregory A. Otterson, Charles L. Shapiro, Jeffrey M. Fowler, Michael R. Grever, Tanios S. Bekaii-Saab, William E. Carson, III JCO Nov 2009: 5270-5277. Abstract Full Text PDF CiteTrack Phase I Pharmacokinetic and Pharmacodynamic Study of the Aurora Kinase Inhibitor Danusertib in Patients With Advanced or Metastatic Solid Tumors Neeltje Steeghs, Ferry A.L.M. Eskens, Hans Gelderblom, Jaap Verweij, Johan W.R. Nortier, Jan Ouwerkerk, Conny van Noort, Mariangela Mariani, Riccardo Spinelli, Patrizia Carpinelli, Bernard Laffranchi, Maja J.A. de Jonge JCO Oct 2009: 5094-5101. Abstract Full Text PDF CiteTrack Phase I and Pharmacokinetic Study of Cetuximab and Irinotecan in Children With Refractory Solid Tumors: A Study of the Pediatric Oncology Experimental Therapeutic Investigators' Consortium Tanya M. Trippett, Cynthia Herzog, James A. Whitlock, Johannes Wolff, John Kuttesch, Rochelle Bagatell, Stephen P. Hunger, Jessica Boklan, Amy A. Smith, Robert J. Arceci, Howard M. Katzenstein, Christopher Harbison, Xiaofei Zhou, Haolan Lu, Christiane Langer, Martin Weber, Lia Gore JCO Oct 2009: 5102-5108. Abstract Full Text PDF CiteTrack Phase I and Biomarker Study of ABT-869, a Multiple Receptor Tyrosine Kinase Inhibitor, in Patients With Refractory Solid Malignancies Chiung-Ing Wong, Tong-San Koh, Ross Soo, Septian Hartono, Choon-Hua Thng, Evelyn McKeegan, Wei-Peng Yong, Chien-Shing Chen, Soo-Chin Lee, John Wong, Robert Lim, Norita Sukri, Siew-Eng Lim, Ai-Bee Ong, Joyce Steinberg, Neeraj Gupta, Rajendra Pradhan, Rod Humerickhouse, Boon-Cher Goh JCO Oct 2009: 4718-4726. Abstract Full Text PDF CiteTrack Phase I/II Trial of AEG35156 X-Linked Inhibitor of Apoptosis Protein Antisense Oligonucleotide Combined With Idarubicin and Cytarabine in Patients With Relapsed or Primary Refractory Acute Myeloid Leukemia Aaron D. Schimmer, Elihu H. Estey, Gautam Borthakur, Bing Z. Carter, Gary J. Schiller, Martin S. Tallman, Jessica K. Altman, Judith E. Karp, Jeannine Kassis, David W. Hedley, Joseph Brandwein, Wei Xu, Duncan H. Mak, Eric LaCasse, Christine Jacob, Stephen J. Morris, Jacques Jolivet, Michael Andreeff JCO Oct 2009: 4741-4746. Abstract Full Text PDF CiteTrack Phase I Drug Combination Trial Design: Walking the Tightrope Paul Hamberg, Jaap Verweij JCO Sep 2009: 4441-4443. Full Text PDF CiteTrack Phase I Study of the Humanized Anti-CD40 Monoclonal Antibody Dacetuzumab in Refractory or Recurrent Non-Hodgkin's Lymphoma Ranjana Advani, Andres Forero-Torres, Richard R. Furman, Joseph D. Rosenblatt, Anas Younes, Hong Ren, Kate Harrop, Nancy Whiting, Jonathan G. Drachman JCO Sep 2009: 4371-4377. Abstract Full Text PDF CiteTrack Pharmacogenetic Pathway Analysis for Determination of Sunitinib-Induced Toxicity Nielka P. van Erp, Karel Eechoute, Astrid A. van der Veldt, John B. Haanen, An K.L. Reyners, Ron H.J. Mathijssen, Epie Boven, Tahar van der Straaten, Renée F. Baak-Pablo, Judith A.M. Wessels, Henk-Jan Guchelaar, Hans Gelderblom JCO Sep 2009: 4406-4412. Abstract Full Text PDF CiteTrack Mapatumumab, an Antibody Targeting TRAIL-R1, in Combination With Paclitaxel and Carboplatin in Patients With Advanced Solid Malignancies: Results of a Phase I and Pharmacokinetic Study Stephen Leong, Roger B. Cohen, Daniel L. Gustafson, Corey J. Langer, D. Ross Camidge, Kristin Padavic, Lia Gore, Margaret Smith, Laura Q. Chow, Margaret von Mehren, Cindy O'Bryant, Sujatha Hariharan, Sami Diab, Norma Lynn Fox, Renée Miceli, S. Gail Eckhardt JCO Sep 2009: 4413-4421. Abstract Full Text PDF CiteTrack Treatment of Fluorouracil-Refractory Patients With Liver Metastases From Colorectal Cancer by Using Yttrium-90 Resin Microspheres Plus Concomitant Systemic Irinotecan Chemotherapy Guy A. van Hazel, Nick Pavlakis, David Goldstein, Ian N. Olver, Michael J. Tapner, David Price, Geoffrey D. Bower, Gregory M. Briggs, Monica A. Rossleigh, D. James Taylor, Jacob George JCO Sep 2009: 4089-4095. Abstract Full Text PDF CiteTrack Phase I Dose Escalation Study of Telatinib, a Tyrosine Kinase Inhibitor of Vascular Endothelial Growth Factor Receptor 2 and 3, Platelet-Derived Growth Factor Receptor β, and c-Kit, in Patients With Advanced or Metastatic Solid Tumors Ferry A.L.M. Eskens, Neeltje Steeghs, Jaap Verweij, Johan L. Bloem, Olaf Christensen, Leni van Doorn, Jan Ouwerkerk, Maja J.A. de Jonge, Johan W.R. Nortier, Joern Kraetzschmar, Prabhu Rajagopalan, Hans Gelderblom JCO Sep 2009: 4169-4176. Abstract Full Text PDF CiteTrack Safety, Pharmacokinetics, and Antitumor Activity of AMG 386, a Selective Angiopoietin Inhibitor, in Adult Patients With Advanced Solid Tumors Roy S. Herbst, David Hong, Linnea Chap, Razelle Kurzrock, Edward Jackson, Jeffrey M. Silverman, Erik Rasmussen, Yu-Nien Sun, Don Zhong, Yuying C. Hwang, Jeffrey L. Evelhoch, Jonathan D. Oliner, NgocDiep Le, Lee S. Rosen JCO Jul 2009: 3557-3565. Abstract Full Text PDF CiteTrack Irinogenetics: How Many Stars Are There in the Sky? Ron H.J. Mathijssen, Howard Gurney JCO Jun 2009: 2578-2579. Full Text PDF CiteTrack Comprehensive Pharmacogenetic Analysis of Irinotecan Neutropenia and Pharmacokinetics Federico Innocenti, Deanna L. Kroetz, Erin Schuetz, M. Eileen Dolan, Jacqueline Ramírez, Mary Relling, Peixian Chen, Soma Das, Gary L. Rosner, Mark J. Ratain JCO Jun 2009: 2604-2614. Abstract Full Text PDF CiteTrack Prospective Validation of a Prognostic Score to Improve Patient Selection for Oncology Phase I Trials Hendrik-Tobias Arkenau, Jorge Barriuso, David Olmos, Joo Ern Ang, Johann de Bono, Ian Judson, Stan Kaye JCO Jun 2009: 2692-2696. Abstract Full Text PDF CiteTrack Phase I Study of Samarium-153 Lexidronam With Docetaxel in Castration-Resistant Metastatic Prostate Cancer Michael J. Morris, Neeta Pandit-Taskar, Jorge Carrasquillo, Chaitanya R. Divgi, Susan Slovin, William K. Kelly, Dana Rathkopf, Gretchen A. Gignac, David Solit, Lawrence Schwartz, Ryan D. Stephenson, Christina Hong, Anthony Delacruz, Tracy Curley, Glenn Heller, Xiaoyu Jia, Joseph O'Donoghue, Steven Larson, Howard I. Scher JCO May 2009: 2436-2442. Abstract Full Text PDF CiteTrack Phase I and Pharmacokinetic Study of Sorafenib in Patients With Hepatic or Renal Dysfunction: CALGB 60301 Antonius A. Miller, Daryl J. Murry, Kouros Owzar, Donna R. Hollis, Erin B. Kennedy, Ghassan Abou-Alfa, Apurva Desai, Jimmy Hwang, Miguel A. Villalona-Calero, E. Claire Dees, Lionel D. Lewis, Marwan G. Fakih, Martin J. Edelman, Fred Millard, Richard C. Frank, Raymond J. Hohl, Mark J. Ratain JCO Apr 2009: 1800-1805. Abstract Full Text PDF Publisher's Note CiteTrack Phase I Trial of AEG35156 Administered as a 7-Day and 3-Day Continuous Intravenous Infusion in Patients With Advanced Refractory Cancer Emma Dean, Duncan Jodrell, Kate Connolly, Sarah Danson, Jacques Jolivet, Jon Durkin, Stephen Morris, Debra Jowle, Tim Ward, Jeff Cummings, Gemma Dickinson, Leon Aarons, Eric LaCasse, Lesley Robson, Caroline Dive, Malcolm Ranson JCO Apr 2009: 1660-1666. Abstract Full Text PDF CiteTrack From Theoretical Synergy to Clinical Supra-Additive Toxicity Jean-Charles Soria, Christophe Massard, Hassane Izzedine JCO Mar 2009: 1359-1361. Full Text PDF CiteTrack Effects of Food on the Relative Bioavailability of Lapatinib in Cancer Patients Kevin M. Koch, Nandi J. Reddy, Roger B. Cohen, Nancy L. Lewis, Bonnie Whitehead, Kathleen Mackay, Andrew Stead, Andrew P. Beelen, Lionel D. Lewis JCO Mar 2009: 1191-1196. Abstract Full Text PDF CiteTrack Iodine-131—Metaiodobenzylguanidine Double Infusion With Autologous Stem-Cell Rescue for Neuroblastoma: A New Approaches to Neuroblastoma Therapy Phase I Study Katherine K. Matthay, Alekist Quach, John Huberty, Benjamin L. Franc, Randall A. Hawkins, Hollie Jackson, Susan Groshen, Suzanne Shusterman, Gregory Yanik, Janet Veatch, Patricia Brophy, Judith G. Villablanca, John M. Maris JCO Mar 2009: 1020-1025. Abstract Full Text PDF CiteTrack Phase I Trial of Interleukin-12 Plasmid Electroporation in Patients With Metastatic Melanoma Adil I. Daud, Ronald C. DeConti, Stephanie Andrews, Patricia Urbas, Adam I. Riker, Vernon K. Sondak, Pamela N. Munster, Daniel M. Sullivan, Kenneth E. Ugen, Jane L. Messina, Richard Heller JCO Dec 2008: 5896-5903. Abstract Full Text PDF Publisher's Note CiteTrack Retinol, Vitamins, and Cancer Prevention: 25 Years of Learning and Relearning Gary E. Goodman, David S. Alberts, Frank L. Meyskens JCO Dec 2008: 5495-5496. Full Text PDF From JCO 1983 CiteTrack [Next page] Pages: 1 2 3 4 5 6 7

Sign up for Collection Alerts Collected Resources Home Related collections: 25th Anniversary Commentaries Art of Oncology Biology of Neoplasia Biostatistics and Clinical Trial Methodology Bone Marrow Transplantation Breast Cancer Cancer-Related Complications Clinical Guidelines Diagnosis and Staging Endocrine System Cancer Epidemiology, Cancer Prevention, and Control Gastrointestinal Cancer Genitourinary Cancer Gynecologic Cancer Head and Neck Cancer Health Services Research Hematologic Malignancies JCO Translations Melanoma Neurooncology Non-Melanoma Skin Cancer Notes from the Editors Patient and Survivor Care Pediatric Oncology Phase I and Clinical Pharmacology Radiation Oncology Sarcomas Surgical Oncology Thoracic Oncology Translational Oncology Treatment-Related Complications Tumor Imaging Unknown Primary Site and Rare Cancers